Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


16.04.2018

1 Anticancer Res
3 BJU Int
1 BMC Cancer
1 Br J Radiol
1 Cancer Lett
1 Clin Imaging
1 Eur Radiol
5 Eur Urol
7 Int J Urol
1 J Clin Oncol
4 J Nucl Med
6 J Urol
1 Nat Rev Urol
3 PLoS One
3 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. PEPE P, Pepe G, Pepe L, Garufi A, et al
    Cost-effectiveness of Multiparametric MRI in 800 Men Submitted to Repeat Prostate Biopsy: Results of a Public Health Model.
    Anticancer Res. 2018;38:2395-2398.
    PubMed     Text format     Abstract available


    BJU Int

  2. CASH H, Steiner U, Heidenreich A, Klotz T, et al
    Intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration resistant prostate cancer (CRPC) - a phase III study (PRINCE).
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14239.
    PubMed     Text format     Abstract available

  3. LANCEE M, Tikkinen KAO, de Reijke TM, Kataja VV, et al
    Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14237.
    PubMed     Text format     Abstract available

  4. BRYANT RJ, Yang B, Philippou Y, Lam K, et al
    Does the introduction of prostate multiparametric MRI into active surveillance of localised prostate cancer improve patient re-classification?
    BJU Int. 2018 Apr 12. doi: 10.1111/bju.14248.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. JONES DZ, Schmidt ML, Suman S, Hobbing KR, et al
    Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
    BMC Cancer. 2018;18:421.
    PubMed     Text format     Abstract available


    Br J Radiol

  6. JADVAR H, Colletti PM
    (18)F-NaF/(223)RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.
    Br J Radiol. 2018 Apr 9:20170948. doi: 10.1259/bjr.20170948.
    PubMed     Text format     Abstract available


    Cancer Lett

  7. CHANG AC, Chen PC, Lin YF, Su CM, et al
    Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin alpha4beta1 system.
    Cancer Lett. 2018 Apr 5. pii: S0304-3835(18)30254.
    PubMed     Text format     Abstract available


    Clin Imaging

  8. BRYCE Y, Santos E
    Balloon pulmonary angioplasty in a patient with prostate cancer and chronic thromboembolic pulmonary hypertension.
    Clin Imaging. 2018;50:185-187.
    PubMed     Text format     Abstract available


    Eur Radiol

  9. LOTTE R, Lafourcade A, Mozer P, Conort P, et al
    Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?
    Eur Radiol. 2018 Apr 9. pii: 10.1007/s00330-018-5352.
    PubMed     Text format     Abstract available


    Eur Urol

  10. GIANNARINI G, Fossati N, Gandaglia G, Cucchiara V, et al
    Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30202.
    PubMed     Text format    

  11. HAIDL F, Heidenreich A, Pfister D
    Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Eur Urol. 2018 Apr 10. pii: S0302-2838(18)30247.
    PubMed     Text format    

  12. VILLERS A, Olivier J
    Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30242.
    PubMed     Text format    

  13. MAURER T, Robu S, Schottelius M, Schwamborn K, et al
    (99m)Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30189.
    PubMed     Text format     Abstract available

  14. CARNEIRO A, Sanchez-Salas R
    Re: Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
    Eur Urol. 2018 Apr 3. pii: S0302-2838(18)30204.
    PubMed     Text format    


    Int J Urol

  15. KITAGAWA Y
    Editorial Comment to Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13578.
    PubMed     Text format    

  16. IZUMI K
    Editorial Comment to Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13572.
    PubMed     Text format    

  17. HASHIMOTO T, Ohori M, Shimodaira K, Kaburaki N, et al
    Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13563.
    PubMed     Text format     Abstract available

  18. BIANCHI L, Schiavina R, Borghesi M, Bianchi FM, et al
    Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13565.
    PubMed     Text format     Abstract available

  19. MEARINI L
    Editorial Comment to Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13575.
    PubMed     Text format    

  20. NAKAJIMA K, Kaneko G, Takahashi S, Matsuyama H, et al
    Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI)
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13556.
    PubMed     Text format     Abstract available

  21. TAKAMOTO A, Tanimoto R, Bekku K, Araki M, et al
    Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13555.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. JANSSON F, Drevin L, Frisell T, Stattin P, et al
    Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer.
    J Clin Oncol. 2018 Apr 13:JCO2017766907. doi: 10.1200/JCO.2017.76.6907.
    PubMed     Text format     Abstract available


    J Nucl Med

  23. AHMADZADEHFAR H, Essler M
    Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing (177)Lu-PSMA therapy.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.209270. doi: 10.2967/jnumed.118.209270.
    PubMed     Text format    

  24. CALAIS J, Kishan AU, Cao M, Fendler WP, et al
    Potential impact of (68)Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning.
    J Nucl Med. 2018 Apr 13. pii: jnumed.118.209387. doi: 10.2967/jnumed.118.209387.
    PubMed     Text format     Abstract available

  25. VARGAS HA, Kramer GM, Scott AM, Weickhardt A, et al
    Reproducibility and repeatability of semi-quantitative (18)F-fluorodihydrotestosterone (FDHT) uptake metrics in castration-resistant prostate cancer metastases: a prospective multi-center study.
    J Nucl Med. 2018 Apr 6. pii: jnumed.117.206490. doi: 10.2967/jnumed.117.206490.
    PubMed     Text format     Abstract available

  26. GRKOVSKI M, Gharzeddine K, Sawan P, Schoder H, et al
    (11)C-choline pharmacokinetics in recurrent prostate cancer.
    J Nucl Med. 2018 Apr 6. pii: jnumed.118.210088. doi: 10.2967/jnumed.118.210088.
    PubMed     Text format     Abstract available


    J Urol

  27. TANEJA SS
    Re: Health-Related Quality of Life for Immediate versus Delayed Androgen-Deprivation Therapy in Patients with Asymptomatic, Non-Curable Prostate Cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): A Randomised, Multicentre, Non-Blinded, Phase 3 Trial.
    J Urol. 2018;199:892-894.
    PubMed     Text format    

  28. TANEJA SS
    Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Urol. 2018;199:893-894.
    PubMed     Text format    

  29. ATALA A
    Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4.
    J Urol. 2018;199:895-896.
    PubMed     Text format    

  30. CADEDDU JA
    Re: Robotic Salvage Retroperitoneal and Pelvic Lymph Node Dissection for 'Node-Only' Recurrent Prostate Cancer: Technique and Initial Series.
    J Urol. 2018;199:875-876.
    PubMed     Text format    

  31. SIEGEL C
    Re: Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.
    J Urol. 2018;199:873.
    PubMed     Text format    

  32. RYAN CJ, Crawford ED, Shore ND, Underwood W 3rd, et al
    The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2018 Apr 6. pii: S0022-5347(18)42900-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  33. LOEB S, Katz MS, Langford A, Byrne N, et al
    Prostate cancer and social media.
    Nat Rev Urol. 2018 Apr 11. pii: 10.1038/s41585-018-0006.
    PubMed     Text format     Abstract available


    PLoS One

  34. RUSSELL B, Garmo H, Beckmann K, Stattin P, et al
    A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.
    PLoS One. 2018;13:e0195690.
    PubMed     Text format     Abstract available

  35. FRYZEK JP, Reichert H, Summers N, Townes L, et al
    Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.
    PLoS One. 2018;13:e0195790.
    PubMed     Text format     Abstract available

  36. GOINEAU A, Campion L, d'Aillieres B, Vie B, et al
    Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
    PLoS One. 2018;13:e0194173.
    PubMed     Text format     Abstract available


    Prostate

  37. GIRI VN, Obeid E, Hegarty SE, Gross L, et al
    Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
    Prostate. 2018 Apr 14. doi: 10.1002/pros.23535.
    PubMed     Text format     Abstract available

  38. KRANZBUHLER B, Salemi S, Umbricht CA, Muller C, et al
    Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
    Prostate. 2018 Apr 6. doi: 10.1002/pros.23522.
    PubMed     Text format     Abstract available

  39. MORI K, Kimura T, Ito K, Onuma H, et al
    Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Prostate. 2018 Apr 10. doi: 10.1002/pros.23534.
    PubMed     Text format     Abstract available


    Urology

  40. LUCKENBAUGH AN, Hollenbeck BK, Kaufman SR, Yan P, et al
    Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
    Urology. 2018 Apr 6. pii: S0090-4295(18)30300.
    PubMed     Text format     Abstract available

  41. VELASQUEZ MC, Chinea FM, Kwon D, Prakash NS, et al
    The Influence of Ethnic Heterogeneity on Prostate Cancer Mortality after Radical Prostatectomy in Hispanic/Latino Men: A Population-Based Analysis.
    Urology. 2018 Apr 6. pii: S0090-4295(18)30293.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: